Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06740383 · ClinicalTrials.gov registry record
Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
A clinical trial of Schizophrenia and Schizoaffective Disorder, sponsored by Beth Israel Deaconess Medical Center.
- Recruiting
- Registry status
- 320
- Enrollment target
- 6
- Study locations
NCT06740383: Recruiting study of Schizophrenia and Schizoaffective Disorder, sponsored by Beth Israel Deaconess Medical Center.
NCT06740383 is a study of Schizophrenia and Schizoaffective Disorder that is actively recruiting participants, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 320 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (47% higher). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06740383, a study of Schizophrenia and Schizoaffective Disorder, is actively recruiting participants, sponsored by Beth Israel Deaconess Medical Center.
- RECRUITING
- Registry status
- 320 participants
- Enrollment target
- 6
- Study locations
Study Summary
The Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS) study aims to understand the early stages of psychotic disorders like Schizophrenia, Schizoaffective Disorder, and Bipolar I Disorder. It involves gathering mental health information, brain scans (MRI), eye movement patterns (Eye-Tracking), and brain electrical waves (EEG) data from individuals who have experienced these disorders in recent years. Participants will be involved for about a year, with four visits over this period. Screening procedures, lasting approximately 3 hours, include tests for drug use, a pregnancy test for eligible women, clinical interviews about feelings and experiences, psychiatric and family history interviews, and a medical history review. Research procedures for eligible participants include DNA collection, a neuropsychological test battery, EEG, eye-tracking, and MRI. These procedures will help researchers understand brain function, genetics, and cognitive abilities related to psychotic disorders. Follow-up visits at 1-month, 6-month, and 12-month intervals involve modified clinical interviews and repeating neuropsychological tests to track changes over time. Participants may opt to provide DNA samples for genetic analysis, undergo various cognitive tests, EEG to record brain waves, eye-tracking to monitor eye movements, and MRI scans to visualize brain structure. Follow-up visits at regular intervals will help researchers track changes in symptoms and cognitive function. This study provides comprehensive insight into the onset and progression of psychotic disorders and offers valuable information for patients, families, and healthcare providers involved in managing these conditions. Our goal is to better understand whether a combination of biological markers and different types of people (BT1, BT2, BT3) can help us predict how well individuals with early psychosis respond to specialized care. We expect that those in BT3 will have the best outcomes, BT2 w
Primary Outcome
\>30% reduction in Positive and Negative Syndrome Scale (PANSS) score
Conditions Studied
Study Locations (6)
Massachusetts
- McLean Hospital - Belmont
- Beth Israel Deaconess Medical Center - Boston
Connecticut
- Hartford Hospital - Hartford
Georgia
- University of Georgia - Athens
Illinois
- University of Chicago Medical Center - Chicago
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2023-01-01 |
| Est. Completion | 2027-06-30 |
What NCT06740383 shows while recruiting
NCT06740383 is an observational study that tracks outcomes without assigning an intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (47% higher).
The record links to 7 conditions, with Schizophrenia appearing as the primary indexed condition, and to 0 interventions.
NCT06740383 lists 6 locations in 5 states (Massachusetts, Connecticut, Georgia).
Frequently Asked Questions
What is clinical trial NCT06740383 about?
NCT06740383 is a clinical study titled "Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services". The Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS) study aims to understand the early stages of psychotic disorders like Schizophrenia, Schizoaffective Disorder, and Bipolar I Disorder. It involves gathering mental health information, brain scans (MRI), eye movement p...
What is the current status of trial NCT06740383?
This trial is currently recruiting. The enrollment target is 320 participants. The study started on 2023-01-01. Estimated completion is 2027-06-30.
What conditions does trial NCT06740383 study?
This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder, Early Psychosis, Bipolar 1 Disorder, Schizophrenia Spectrum and Other Psychotic Disorders.
Who is sponsoring clinical trial NCT06740383?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06740383 being conducted?
This trial has 6 study locations across Connecticut, Georgia, Illinois, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06740383's enrollment target sits among peer trials
320 54th of 315 higher than 262 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI